This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Leo, V. Articles by Morgante, G. Search for Related Content PubMed PubMed Citation Articles by De Leo, V. Articles by Morgante, G.

Effect of Metformin on Insulin-Like Growth Factor (IGF) I and IGF-Binding Protein I in Polycystic Ovary Syndrome

Department of Obstetrics and Gynecology (V.D.L., A.l.M., G.M.), University of Siena, 53100 Siena, Italy; and Department of Obstetrics and Gynecology (R.O.), Rabin Medical Center (Golda Campus), Petah Tikva, Israel

Address all correspondence and requests for reprints to: Vincenzo De Leo, M.D., Department of Obstetrics and Gynecology, University of Siena, Policlinico Le Scotte, Viale Bracci, 53100 Siena (SI), Italy. E-mail: deleo{at}unisi.it

The objective of the present study was to investigate whether metformin affected plasma concentrations of insulin-like growth factor (IGF) I and IGF-binding protein I (IGFBP-I) in polycystic ovary syndrome (PCOS) patients. This was an open study conducted by the Department of Obstetrics and Gynecology at the University of Siena, Italy. Seventeen women with PCOS participated in the study and were administered metformin at a dose of 500 mg three times a day. Treatment was continued for 30–32 days, after which the pretreatment evaluation was repeated. Plasma concentrations of LH, FSH, estradiol, free testosterone, IGF-I, IGFBP-I, sex hormone-binding globulin, and insulin were evaluated. Metformin led to a significant reduction in areas under the insulin curves (9310 ± 1509 vs. 6520 ± 1108 mU/mL·min; P < 0.05) and was associated with a decrease in plasma free testosterone levels (12.7 ± 1.7 vs. 10.3 ± 2 pg/mL; P < 0.05) and an increase in plasma sex hormone-binding globulin concentrations (62 ± 8 vs. 94 ± 13 nmol/L; P < 0.05). A nonsignificant increase in plasma IGF-I levels was observed after metformin (276 ± 48 vs. 291 ± 71 mcg/L), with a significant increase in plasma IGFBP-I levels (0.56 ± 0.2 vs. 0.98 ± 0.38 mcg/L; P < 0.05). The IGF-I/IGFBP-I ratio was significantly lower (492.8 ± 117 vs. 296.9 ± 82; P < 0.05) at the end of therapy than before treatment. In conclusion, it seems to be appropriate to intervene with an insulin-sensitizing agent such as metformin in an attempt to break the pathogenetic link between hyperinsulinemia and hormonal perturbations in PCOS.

This article has been cited by other articles:

				S. Ten and N. Maclaren Insulin Resistance Syndrome in Children J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2526 - 2539. [Abstract] [Full Text] [PDF]

				V. BRUNI, M. DEI, V. PONTELLO, and P. VANGELISTI The Management of Polycystic Ovary Syndrome Ann. N.Y. Acad. Sci., November 1, 2003; 997(1): 307 - 321. [Abstract] [Full Text] [PDF]

				V. De Leo, A. la Marca, and F. Petraglia Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome Endocr. Rev., October 1, 2003; 24(5): 633 - 667. [Abstract] [Full Text] [PDF]

				L. Harborne, R. Fleming, H. Lyall, N. Sattar, and J. Norman Metformin or Antiandrogen in the Treatment of Hirsutism in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4116 - 4123. [Abstract] [Full Text] [PDF]

				A. Shobokshi and M. Shaarawy Correction of Insulin Resistance and Hyperandrogenism in Polycystic Ovary Syndrome By Combined Rosiglitazone and Clomiphene Citrate Therapy Reproductive Sciences, February 1, 2003; 10(2): 99 - 104. [Abstract] [PDF]

				S. A. Arslanian, V. Lewy, K. Danadian, and R. Saad Metformin Therapy in Obese Adolescents with Polycystic Ovary Syndrome and Impaired Glucose Tolerance: Amelioration of Exaggerated Adrenal Response to Adrenocorticotropin with Reduction of Insulinemia/Insulin Resistance J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1555 - 1559. [Abstract] [Full Text] [PDF]

				V. De Leo, A. la Marca, G. Morgante, L. Ciotta, L. Mencaglia, A. Cianci, and F. Petraglia Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome Hum. Reprod., November 1, 2000; 15(11): 2302 - 2305. [Abstract] [Full Text] [PDF]

				S. E. Oberfield Metabolic Lessons from the Study of Young Adolescents with Polycystic Ovary Syndrome--Is Insulin, Indeed, the Culprit? J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3520 - 3525. [Full Text]